Monographed dilute phosphoric acid contains 9.5–10.5% w/w H₃PO₄; in drinking-water medication systems for swine and poultry, this specification is the dosing basis when acid-stable anti-infectives require a final dilution pH of 3.2–4.0 for solubility retention and prevention of microbial regrowth in standing medicated water. The addition ratio at the stock-solution stage is 0.05–1.5% w/w based on total batch mass; a metering pump with pH-proportional feedback maintains pH 3.5 ± 0.3 during recirculation through 2,000–10,000 L 316L stainless mixing vessels. Production operators continuously monitor conductivity and pH per USP <791>, because over-dosing above 1.8% w/w can depress pH below 2.8 and interact with residual hypochlorite in potable water lines to release chlorine. At the target pH window, the H₃PO₄/H₂PO₄⁻ equilibrium dominates because pH lies above pKa₁ 2.15 and below pKa₂ 7.20, providing buffering without fully consuming the second acidic proton. Compliance is evaluated under VICH GL3R stability requirements, with final release including Ph. Eur. 2.2.3 potentiometric pH determination and elemental impurity control according to the diluted phosphoric acid monograph. Terminal product types include oral drench solutions, drinking-water concentrates, and rehydration solutions with electrolytes where the acidulant is added before citric acid to buffer the final solution without chelating calcium. Contact with carbon steel should be avoided after dilution because the acid promotes iron leaching at pH below 4.0.

pH Adjustment Boundaries in Large Animal Parenterals

Sterile injectable manufacturing with 10% w/w diluted phosphoric acid veterinary grade uses the acid as q.s. pH adjustment after API dissolution in Water for Injection at 18–25°C; final pH is fixed by API solubility and tissue-tolerance data, usually 4.0–6.5 for intramuscular and subcutaneous preparations and 5.5–7.0 for intravenous formulations unless the active requires a lower pH to remain in solution. The addition ratio is 0.01–0.05% w/w of the final batch size, added through a peristaltic metering line into a 316L buffer tank under nitrogen overlay to prevent carbonate pickup; batch records from 50–500 L aseptic filling operations show that a pH overshoot below 3.8 is difficult to correct with 1 M sodium hydroxide without causing local precipitation at the addition point. Compliance requires bulk solution sampling according to Ph. Eur. 2.6.14 for bacterial endotoxins and final product release per USP <788> particulate matter and USP <85> bacterial endotoxin test, with stability under VICH GL3R; terminal sterilisation by autoclave at 121°C/15 min is used only after confirming no acid-catalysed hydrolysis of the active. Terminal product types are parenteral solutions in Type I glass vials or blow-fill-seal LDPE ampoules from 10 mL to 500 mL. Amine-based local anaesthetics and benzyl alcohol co-solvents can form insoluble salts or phase splits below pH 4.0.

What Limits Wet-Granulation Acid Choice for Veterinary Tablets and Boluses?

In wet granulation of veterinary tablets and rumen boluses, 10% w/w diluted phosphoric acid is applied to the binder solution at 0.1–1.5% w/w of dry-blend mass; this range is selected because below 0.1% w/w the granule pH remains above 5.5 and the dissolution benefit for acid-stable APIs disappears, while above 1.5% w/w the pH falls below 3.0 and hydrolytic attack on cellulosic binders leads to weak granules. The production sequence in a high-shear granulator with impeller speed 300–800 rpm and chopper 1500–3000 rpm is: dry blending 3–5 min, spraying the acidified binder solution at 0.5–1.5 L/min, wet massing 3–6 min, then transfer to a fluid-bed dryer with inlet air 55–65°C until loss-on-drying reaches 1.5–2.5% w/w. Granule pH is measured on a 10% w/w aqueous slurry with USP <791>; tablet compression uses 10–25 kN force and target hardness 80–150 N for boluses and 50–100 N for standard tablets. Release testing includes Ph. Eur. 2.9.5 mass uniformity, Ph. Eur. 2.9.7 friability, and Ph. Eur. 2.9.8 disintegration; stability studies follow VICH GL3R. Terminal product types are film-coated tablets, chewable tablets, and large-animal rumen boluses. If excipient pre-drying is not performed at relative humidity above 60%, the acidified binder may add too much moisture and cause lumping in the subsequent cone mill.

Effervescent Granule Stoichiometry and Moisture Exclusion

Effervescent veterinary granules and tablets containing 10% w/w diluted phosphoric acid are designed around an acid-base stoichiometry in which 1 mL of the acid, with density 1.05 g/mL, carries 0.105 g H₃PO₄ and neutralizes 0.18–0.27 g sodium bicarbonate depending on the number of dissociated protons consumed before the final solution pH reaches 3.5–5.0. In production, the liquid acid is sprayed onto a pre-blend of sodium bicarbonate, sodium carbonate, filler, and binder under dehumidified air at RH<20% and 18–22°C inside a low-shear granulator; the granulate is then screened through a 0.8–1.5 mm cone mill and dried in a fluid bed at 30–40°C to final moisture <0.5% w/w. Tablet compression is performed at 10–25 kN with 316L or Stellite-tipped punches because uncoated tooling pits under acid contact. Hardness is maintained at 60–120 N; low hardness causes lamination on rotary presses, while high hardness increases disintegration time beyond the limit of Ph. Eur. 2.9.8. Stability protocols follow VICH GL3R with packaging in HDPE containers with desiccant and induction-sealed caps; compressed air quality is controlled to ISO 8573-1 Class 2.2.2 to prevent moisture ingress. Terminal product types are effervescent powders for drinking-water use, effervescent granules in single-dose sachets, and effervescent tablets. Alkaline phosphates and calcium carbonate should not be co-granulated with the acid unless a hydrophobic barrier coating is applied to the carbonate particles.

For acidified hard-capsule powders intended for companion animals, 10% w/w diluted phosphoric acid is applied at 0.05–0.8% w/w onto an adsorbed carrier such as microcrystalline cellulose or colloidal silicon dioxide before blending with active granules; this pre-acidified carrier route avoids localized acid pockets and prevents gelatin capsule shell brittleness when shell moisture falls below 6% w/w. The carrier is sprayed in a low-shear mixer at 10–25 rpm for 5–10 min, then blended with the remaining excipients in a 500 L bin blender at 10–15 rpm for 15–25 min; fill-mass pH is checked after extraction in 0.05 M phosphate buffer using USP <791>. Capsule filling is performed on a dosator-type machine at 24–26°C and 35–45% RH; plug thickness is adjusted to 2–6 mm depending on powder compressibility. Release testing includes Ph. Eur. 2.9.5 mass uniformity and Ph. Eur. 2.9.6 content uniformity, and stability studies follow VICH GL3R; published data for acid-sprayed capsule fill at this specific addition range is limited, so batch-specific uniformity is verified before scale-up. Terminal product types are hard capsules in sizes 0–4, acid-coated multi-particulate capsules, and capsule-in-capsule formats where an acid-resistant subcoat controls the site of release. If pH is below 3.0, gelatin shells stored above 45% RH may soften; if pH above 5.5, the dissolution benefit is lost.

When a Veterinary Premix Requires Acid-Stable Trace Mineral Co-Delivery

In medicated premixes and oral powders that contain acid-sensitive trace minerals, 10% w/w diluted phosphoric acid is used at 0.01–0.5% w/w as a carrier-surface acidulant to reduce free-water activity and control caking when zinc oxide, copper sulfate, or manganese carbonate are present. The sequence in a horizontal ribbon mixer with L/D 2:1 and tip speed 1.2–2.0 m/s is carrier loading, acid spray at 0.05–0.2% w/w, blending 5–10 min, mineral addition, active addition, and final blending 10–15 min; total batch moisture is capped at <2.0% w/w by Karl Fischer titration because water introduced with the acid must be removed by carrier adsorption or vacuum drying. The final premix is diluted 1:100 in water for pH verification using USP <791>, and the pH after dilution should fall between 3.8 and 5.5 for most in-feed antimicrobial stability windows. Compliance references 21 CFR 582.1073 for phosphoric acid as GRAS and EU Regulation 1831/2003 for veterinary premix registration; release includes Ph. Eur. 2.9.5 mass uniformity and residual moisture by USP <921>. Terminal product types are medicated feed premixes, water-soluble oral powders, and top-dress granules. Do not blend with calcium carbonate or sodium bicarbonate in the same pre-blend because neutralization forms insoluble calcium phosphate and releases CO₂ inside the packaging.